Haemonetics (NYSE:HAE) had its price objective raised by Jefferies Group from $18.00 to $75.00 in a research report report published on Monday morning, The Fly reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock. Jefferies Group also issued estimates for Haemonetics’ Q3 2018 earnings at $0.45 EPS, Q4 2018 earnings at $0.40 EPS, FY2018 earnings at $1.66 EPS, FY2019 earnings at $2.00 EPS, FY2020 earnings at $2.80 EPS, FY2021 earnings at $3.75 EPS and FY2022 earnings at $4.35 EPS.

HAE has been the subject of several other research reports. Zacks Investment Research cut Haemonetics from a buy rating to a hold rating in a research note on Monday, November 20th. Morgan Stanley reissued an equal weight rating and issued a $43.00 price target (up previously from $38.00) on shares of Haemonetics in a research note on Friday, October 6th. Raymond James Financial raised Haemonetics from an underperform rating to a market perform rating in a research note on Tuesday, January 2nd. Craig Hallum reissued a hold rating and issued a $50.00 price target (up previously from $40.00) on shares of Haemonetics in a research note on Wednesday, November 8th. Finally, Barrington Research upped their target price on Haemonetics from $48.00 to $57.00 and gave the company an outperform rating in a research report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $58.83.

Haemonetics (HAE) opened at $64.76 on Monday. Haemonetics has a fifty-two week low of $36.44 and a fifty-two week high of $64.76. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.51. The stock has a market capitalization of $3,420.00, a PE ratio of 925.14, a price-to-earnings-growth ratio of 4.71 and a beta of 0.99.

Haemonetics (NYSE:HAE) last issued its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.07. Haemonetics had a return on equity of 11.16% and a net margin of 0.50%. The business had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $219.12 million. During the same quarter in the prior year, the firm earned $0.38 EPS. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. equities analysts forecast that Haemonetics will post 1.7 earnings per share for the current year.

In other Haemonetics news, CAO Dan Goldstein sold 4,691 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $54.93, for a total value of $257,676.63. Following the transaction, the chief accounting officer now owns 3,747 shares in the company, valued at $205,822.71. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Susan Bartlett Foote sold 16,926 shares of the stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $54.19, for a total value of $917,219.94. Following the completion of the transaction, the director now owns 27,313 shares in the company, valued at approximately $1,480,091.47. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,486 shares of company stock worth $3,050,827. 1.20% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in HAE. Riverhead Capital Management LLC boosted its holdings in Haemonetics by 79.3% in the second quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock worth $135,000 after acquiring an additional 1,507 shares in the last quarter. Pacad Investment Ltd. bought a new position in Haemonetics in the second quarter worth approximately $174,000. Shelton Capital Management bought a new position in Haemonetics in the second quarter worth approximately $204,000. Cubist Systematic Strategies LLC bought a new position in Haemonetics in the second quarter worth approximately $260,000. Finally, Amalgamated Bank boosted its holdings in Haemonetics by 5.7% in the second quarter. Amalgamated Bank now owns 7,322 shares of the medical instruments supplier’s stock worth $289,000 after acquiring an additional 392 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “Jefferies Group Raises Haemonetics (HAE) Price Target to $75.00” was posted by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.watchlistnews.com/jefferies-group-raises-haemonetics-hae-price-target-to-75-00/1804162.html.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

The Fly

Analyst Recommendations for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.